Publications by authors named "Anna Fettiplace"

Claim this Profile
H
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.
Anna Fettiplace, Arie Regev, Alexandre Kiazand, Ulrike Heinzel-Pleines, Mahnoush Bahjat

Drug Saf· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi

Aliment Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.
Eric B Cohen, Arie Regev, Anju Garg, Adrian M Di Bisceglie, James H Lewis, Anna Fettiplace

Drug Saf· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.
Anna Fettiplace, Sherri Matis-Mitchell, Oleksandr Molodetskyi, Malin Söderbergh, Jan Oscarsson

Expert Opin Drug Saf· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests.
Michael Merz, Anna Fettiplace, John Marcinak, Hans L Tillmann, Don C Rockey

Expert Opin Drug Saf· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Anna Fettiplace

Lancet· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis